The included appraisals concerned eleven indications including PD-L1 expression, eight for ALK mutations, six for EGFR mutations, two for the ROS1 oncogene, one for NSCLC of adenocarcinoma histology (nintedanib), one for previously treated NSCLC (ramucirumab), and one for maintenance treatment for NSCLC (pemetrexed). This evidence concerns the gene ROS1 and adenocarcinoma.